Daix (France), Long Island City (New
York, United States), May 26, 2023 – Inventiva (Euronext
Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company
focused on the development of oral small molecule therapies for the
treatment of non-alcoholic steatohepatitis (NASH) and other
diseases with unmet medical need, today announced the results of
the votes of its Combined Shareholders’
Meeting.
The Combined Shareholders' Meeting was held on
Thursday May 25, 2023 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue
Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric
Cren, Chairman and Chief Executive Officer and cofounder of
Inventiva.
Mr. Frederic Cren proceeded to the usual
formalities of the opening of the meeting, in particular to the
constitution of the Bureau by appointing Mrs. Christelle Herbin and
Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as
secretary of the general meeting.
All the resolutions submitted to vote have been
adopted by the shareholders. Pursuant to Article R. 22-10-14 IV. of
the French Commercial Code, the Combined Shareholders’ Meeting
approved, without modification, the compensation policy for
corporate officers as presented in the 2022 Universal Registration
Document (Part 3.5.1, pages 160 and seq.).
Information on the results of the votes is
detailed below:
- Total number of shares composing the share capital: 42 134
169
- Total number of shares with voting rights:
41 992 149
|
Ordinary part |
Extraordinary part |
Shareholders |
Shares |
Votes |
Shareholders |
Shares |
Votes |
|
Shareholders present |
5 |
10 614 |
12 814 |
5 |
10 614 |
12 814 |
|
Proxy to third parties |
0 |
0 |
0 |
0 |
0 |
0 |
|
Proxy to the Chairman |
143 |
2 005 685 |
2 100 705 |
143 |
2 005 685 |
2 100 705 |
|
Mail votes |
95 |
31 296 174 |
43 460 424 |
95 |
31 296 174 |
43 460 424 |
|
TOTAL |
243 |
33 312 473 |
45 573 943 |
243 |
33 312 473 |
45 573 943 |
|
Quorum |
79,33 % |
79,33 % |
VOTE RESULTSOrdinary Resolutions
|
Resolution |
Result |
For |
Against |
Abstention |
Total number of votes cast |
Number of represented shares |
Proportion of represented share capital |
Non- voting votes |
Invalid votes |
Quorum |
Votes |
% |
Votes |
% |
Votes |
% |
1 |
Adopted |
45 561 266 |
> 99,99 % |
3 578 |
< 0,01 % |
9 099 |
- |
45 564 844 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
2 |
Adopted |
45 561 266 |
> 99,99 % |
3 578 |
< 0,01 % |
9 099 |
- |
45 564 844 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
3 |
Adopted |
45 560 906 |
99,99 % |
5 938 |
0,01 % |
7 099 |
- |
45 566 844 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
4 |
Adopted |
45 532 185 |
99,99 % |
5 578 |
0,01 % |
36 180 |
- |
45 537 763 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
5 |
Adopted |
45 560 034 |
99,99 % |
4 585 |
0,01 % |
9 324 |
- |
45 564 619 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
6 |
Adopted |
45 365 367 |
99,56 % |
200 747 |
0,44 % |
7 829 |
- |
45 566 114 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
7 |
Adopted |
45 365 367 |
99,56 % |
200 747 |
0,44 % |
7 829 |
- |
45 566 114 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
8 |
Adopted |
45 127 131 |
99,05 % |
434 133 |
0,95 % |
12 679 |
- |
45 561 264 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
9 |
Adopted |
44 466 019 |
97,59 % |
1 100 095 |
2,41 % |
7 829 |
- |
45 566 114 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
10 |
Adopted |
44 466 019 |
97,59 % |
1 100 095 |
2,41 % |
7 829 |
- |
45 566 114 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
11 |
Adopted |
45 335 107 |
99,49 % |
231 007 |
0,51 % |
7 829 |
- |
45 566 114 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
12 |
Adopted |
44 690 251 |
98,07 % |
879 938 |
1,93 % |
3 754 |
- |
45 570 189 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
14 |
Adopted |
45 565 197 |
99,99 % |
6 268 |
0,01 % |
2 478 |
- |
45 571 465 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
VOTE RESULTSExtraordinary
Resolution |
Resolution |
Result |
For |
Against |
Abstention |
Total number of votes cast |
Number of represented shares |
Proportion of represented share capital |
Non-voting votes |
Invalid votes |
Quorum |
Votes |
% |
Votes |
% |
Votes |
% |
13 |
Adopted |
45 321 978 |
99,45 % |
251 611 |
0,55 % |
354 |
- |
45 573 589 |
33 312 473 |
79,062 % |
0 |
0 |
79,330 % |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH,
mucopolysaccharidoses (“MPS”) and other diseases with significant
unmet medical need. The Company benefits from a strong expertise
and experience in the domain of compounds targeting nuclear
receptors, transcription factors and epigenetic modulation.
Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other
development opportunities to add to its pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting an oncology development candidate for its
Hippo signaling pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaPascaline ClercVP of Global External
Affairs media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupTristan Roquet Montegon Aude
LepreuxMatthieu BenoistMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, forecasts and estimates with respect to
Inventiva’s pre-clinical programs and clinical trials, including
design, duration, timing, recruitment costs, screening and
enrollment for those trials, including the ongoing NATiV3 Phase III
clinical trial with lanifibranor in NASH, the LEGEND Phase IIa
combination trial with lanifibranor and empagliflozin in patients
with NASH and type 2 diabetes and the study with lanifibranor in
patients with NAFLD and T2D, potential development of and
regulatory pathway for odiparcil, clinical trial data releases and
publications, the information, insights and impacts that may be
gathered from clinical trials, the potential therapeutic benefits
of Inventiva’s product candidates, including lanifibranor,
potential regulatory submissions and approvals, and Inventiva’s
pipeline and preclinical and clinical development plans, future
activities, expectations, plans, growth and prospects of Inventiva,
the potential receipt of the second tranche under the EIB loan and
any potential transaction or receipt of additional funds, future
access to the two-year short-term deposit, and the
sufficiency of Inventiva’s cash resources and estimated cash
runway. Certain of these statements, forecasts and estimates can be
recognized by the use of words such as, without limitation,
“believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”,
“estimates”, “may”, “will”, “would”, “could”, “might”, “should”,
“designed”, “hopefully”, “target”, “aim”, and “continue” and
similar expressions. Such statements are not historical facts but
rather are statements of future expectations and other
forward-looking statements that are based on management's beliefs.
These statements reflect such views and assumptions prevailing as
of the date of the statements and involve known and unknown risks
and uncertainties that could cause future results, performance or
future events to differ materially from those expressed or implied
in such statements. Actual events are difficult to predict and may
depend upon factors that are beyond Inventiva's control. There can
be no guarantees with respect to pipeline product candidates that
the clinical trial results will be available on their anticipated
timeline, that future clinical trials will be initiated as
anticipated, that product candidates will receive the necessary
regulatory approvals, or that any of the anticipated milestones by
Inventiva or its partners will be reached on their expected
timeline, or at all. Future results may turn out to be
materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, in the absence of which, Inventiva may be required
to significantly curtail, delay or discontinue one or more of its
research or development programs or be unable to expand its
operations or otherwise capitalize on its business opportunities
and may be unable to continue as a going concern, Inventiva's
future success is dependent on the successful clinical development,
regulatory approval and subsequent commercialization of current and
any future product candidates, preclinical studies or earlier
clinical trials are not necessarily predictive of future results
and the results of Inventiva's clinical trials may not support
Inventiva's product candidate claims, Inventiva’s expectations with
respect to the changes to the clinical development plan for
lanifibranor for the treatment of NASH may not be realized and may
not support the approval of a New Drug Application, Inventiva may
encounter substantial delays in its clinical trials or Inventiva
may fail to demonstrate safety and efficacy to the satisfaction of
applicable regulatory authorities, the ability of Inventiva to
recruit and retain patients in clinical studies, enrollment and
retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current geopolitical events, such as
the conflict between Russia and Ukraine, related sanctions and
related impacts and potential impacts on the initiation, enrollment
and completion of Inventiva’s clinical trials on anticipated
timelines, health epidemics, and macroeconomic conditions,
including global inflation, rising interest rates, uncertain
financial markets and disruptions in banking systems. Given these
risks and uncertainties, no representations are made as to the
accuracy or fairness of such forward-looking statements, forecasts
and estimates. Furthermore, forward-looking statements, forecasts
and estimates only speak as of the date of this press release.
Readers are cautioned not to place undue reliance on any of these
forward-looking statements.
Please refer to the Universal Registration Document for the year
ended December 31, 2022 filed with the Autorité des Marchés
Financiers on March 30, 2023, and the Annual Report on Form 20-F
for the year ended December 31, 2022 filed with the Securities and
Exchange Commission on March 30, 2023 for other risks and
uncertainties affecting Inventiva, including those described from
time to time under the caption “Risk Factors”. Other risks and
uncertainties of which Inventiva is not currently aware may also
affect its forward-looking statements and may cause actual results
and the timing of events to differ materially from those
anticipated.
All information in this press release is as of the date of the
release. Except as required by law, Inventiva has no intention and
is under no obligation to update or review the forward-looking
statements referred to above.
- Inventiva - PR - Results AG May 2023 - EN - 05 26 2023
Inventiva (EU:IVA)
Historical Stock Chart
From Apr 2024 to May 2024
Inventiva (EU:IVA)
Historical Stock Chart
From May 2023 to May 2024